Hansoh Pharmaceutical Group
Hansoh Pharmaceutical Group is a Chinese pharmaceutical company focused on oncology, metabolism, immunology, central nervous system diseases, and anti-infectives.
- Public company
- Shanghai, CNChina
Hansoh Pharmaceutical Group is a Chinese pharmaceutical company focused on oncology, metabolism, immunology, central nervous system diseases, and anti-infectives.
hspharm.comCrawled Oct 23, 2026
The European Lung Cancer Congress (ELCC) 2023 will
Recently, the internationally renowned pharmacolog
On March 1, 2023, the National Reimbursable Drug L
Hansoh Pharma, founded in 1995, operates as a pharmaceutical company specializing in research, manufacturing, and sales, with a focus on oncology, CNS, anti-infectives, and diabetes.
Roche partners with Hansoh Pharma for a high-value antibody-drug conjugate (ADC) collaboration, with milestone payments potentially reaching **$15 billion**. The Swiss firm expands its China focus while delaying major investment decisions in Germany. China’s push to retain biotech expertise contrasts with Roche’s shifting priorities, raising questions about Germany’s role in the company’s future strategy.
Oct 2026European Biotechnology MagazineNews article
Hansoh Pharma partners with Roche to collaborate on and license a portfolio of antibody-drug conjugate programs. The agreement spans multiple therapeutic candidates under development by Hansoh Pharma. Roche gains access to Hansoh’s proprietary oncology treatments through this multi-billion-dollar deal.
Oct 2026pharmexec.comNews article
Hansoh Pharma and Roche finalize a licensing agreement for cancer drug development, covering global markets outside China, Hong Kong, Macau, and Taiwan. The deal includes a $400 million upfront payment to Hansoh while securing exclusive rights for Roche in the remaining regions. Both companies retain development and commercialization control over their respective territories.
Oct 2026QuartzNews article
GSK’s antibody-drug conjugate **ris-rez** demonstrates encouraging early results in treating small cell lung cancer, according to new data from an international trial. The findings align with prior outcomes from a Chinese study targeting the same B7-H3 protein. Ris-rez combines a monoclonal antibody with a cytotoxic payload to selectively attack cancer cells.
Oct 2026pharmaphorumNews article